Russian Journal of AllergyRussian Journal of AllergyРоссийский Аллергологический Журнал1810-88302686-682XPublishing House ABV Press146210.36691/RJA1462ReviewsНаучные обзорыReview ArticleModern H1- antihistamines in the treatment of allergic rhinitis: focus on bilastineСовременные Н1-антигистаминные препараты в лечении аллергического ринита: в центре внимания биластинhttps://orcid.org/0000-0002-8574-68698036-2985EmelyanovAlexander V.ЕмельяновАлександр Викторович
Russian Federation

MD, Dr. Sci. (Med.), Professor

доктор медицинских наук, профессор, зав. кафедрой пульмонологии

emelav@inbox.ruhttps://orcid.org/0000-0003-1544-43362474-2933SergeevaGalina R.СергееваГалина Раисовна
Russian Federation

Cand. Sci. (Med.), Assistant

кандидат медицинских наук, доцент

sergreevagr@mail.ruhttps://orcid.org/0000-0003-4616-31661078-6570LeshenkovaEvgenia V.ЛешенковаЕвгения Владиславовна
Russian Federation

MD, Cand. Sci. (Med.)

кандидат медицинских наук

leshenkova@mail.ruNorth-Western Medical University named after I.I. MechnikovСеверо-Западный государственный медицинский университет им. И. И. Мечникова100620212606202118266762505202102062021Copyright ©; 2021, Pharmarus Print MediaCopyright ©; 2021, Фармарус Принт Медиа2021Pharmarus Print MediaФармарус Принт Медиаhttps://rusalljournal.ru/raj/article/view/1462

The second generation of H1-antihistamines is approved for the stepwise treatment of seasonal and perennial allergic rhinitis in adults and children by international and national guidelines. They reduce the severity of nasal and ocular symptoms of rhinitis and improve the quality of life of patients.

Bilastine, a piperidine derivative, is a novel H1-antihistamine. It has a potent and selective effect on H1- receptors and a rapid onset and long duration of action and substantially reduces nasal and ocular symptoms of seasonal and perennial allergic rhinitis. Bilastine has no clinically substantial hepatic metabolism and has a high safety profile: it has no sedative effect, does not affect cognitive functions, has no cardiotoxic effects, and does not interact with alcohol and benzodiazepines in normal and high doses. Tachyphylaxis does not develop despite long-term (up to 1 year) use.

Bilastine is registered for clinical use in adults and children aged >12 years. The results of clinical and experimental studies have demonstrated that bilastine has many of the features of modern H1-antihistamines recommended by international guidelines.

Н1-антигистаминные препараты II поколения рекомендованы международными и национальными документами для ступенчатой терапии сезонного и круглогодичного аллергического ринита у взрослых и детей. Они достоверно уменьшают выраженность назальных и глазных симптомов ринита, а также улучшают качество жизни пациентов.

К числу современных Н1-антигистаминных препаратов относится биластин, который является производным пиперидина. Он обладает сильным и селективным воздействием на Н1-рецепторы, быстрым началом и большой продолжительностью действия, эффективностью в отношении назальных и глазных симптомов сезонного и круглогодичного аллергического ринита. Биластин не имеет клинически значимого печёночного метаболизма, характеризуется высоким профилем безопасности (отсутствие седативного эффекта, влияния на когнитивные функции, кардиотоксичности, взаимодействия с алкоголем и бензодиазепинами в обычных и высоких дозах). К нему не развивается тахифилаксия при длительном (до 1 года) приёме. Препарат зарегистрирован для клинического применения у взрослых и детей с 12 лет. Результаты многочисленных клинических и экспериментальных исследований свидетельствуют о том, что биластин обладает свойствами, предъявляемыми международными руководствами к современным Н1-антигистаминным препаратам.

Rhinitisallergichistamine antagonistsbilastineаллергический ринитантигистаминные препараты II поколениябиластинBousquet J, van Cavuwenberge P, Khaltaev N, et al. Allergic rhinitis and its impact on asthma (ARIA). J Allergy Clin Immunol. 2001;108(5 Suppl.):S.147–S.334. doi: 10.1067/mai.2001.118891Bousquet J., van Cavuwenberge P., Khaltaev N., et al. Allergic rhinitis and its impact on asthma (ARIA) // J Allergy Clin Immunol. 2001. Vol. 108, N 5, suppl. Р. 147-334. doi: 10.1067/mai.2001.118891Bousquet J, Schünemann HJ, Togias A, et al.; Allergic Rhinitis and Its Impact on Asthma Working Group. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145(1):70–80.e3. doi: 10.1016/j.jaci.2019.06.049Bousquet J., Schünemann H.J., Togias A., et al.; Allergic Rhinitis and Its Impact on Asthma Working Group. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence // J Allergy Clin Immunol. 2020. Vol. 145, N 1. Р. 70–80.e3. doi: 10.1016/j.jaci.2019.06.049Papadopoulos NG, Bernstein JA, Demoly P. Phenotypes and endotypes of rhinitis and their impact on management: a PRACTALL report. Allergy. 2015;70(5):474–494. doi: 10.1111/all.12573Papadopoulos N.G., Bernstein J.A., Demoly P. Phenotypes and endotypes of rhinitis and their impact on management: a PRACTALL report // Allergy. 2015. Vol. 70, N 5. Р. 474–494. doi: 10.1111/all.12573Bousquet PJ, Combescure C, Klossek JM, et al. Change in visual analog scale score in a pragmatic randomized cluster trial of allergic rhinitis. J Allergy Clin Immunol. 2009;123(6):1349–1354. doi: 10.1016/j.jaci.2009.02.033Bousquet P.J., Combescure C., Klossek J.M., et al. Change in visual analog scale score in a pragmatic randomized cluster trial of allergic rhinitis // J Allergy Clin Immunol. 2009. Vol. 123, N 6. Р. 1349–1354. doi: 10.1016/j.jaci.2009.02.033Eguiluz-Gracia I, Testera-Montes A, Rondon C. Medical algorithm: Diagnosis and treatment of local allergic rhinitis. Allergy. 2021. doi: 10.1111/all.14848Eguiluz-Gracia I., Testera-Montes A., Rondon C. Medical algorithm: Diagnosis and treatment of local allergic rhinitis // Allergy. 2021. doi: 10.1111/all.14848Nenasheva NM, Shilenkova VV. Control of symptoms of allergic rhinitis in adults in the Russian Federation: results of an online survey. RMJ “Medical review”. 2021;51(1):25–31. (In Russ). doi: 10.32364/2587-6821-2021-5-1-25-31Ненашева Н.М., Шиленкова В.В. Контроль симптомов аллергического ринита у взрослых лиц в Российской Федерации: результаты онлайн-опроса // РМЖ «Медицинское обозрение». 2021. Т. 51, № 1. С. 25–31. doi: 10.32364/2587-6821-2021-5-1-25-31Polner SA. Federal clinical recommendations: Allergic rhinitis. Russian Allergological Journal. 2017;14(2):47–54. (In Russ). doi: 10.36691/RJA323Польнер С.А. Федеральные клинические рекомендации: Аллергический ринит // Российский Аллергологический Журнал. 2017. Т. 14, № 2. С. 47–54. doi: 10.36691/RJA323Farre M, Perez-Manna C, Papaseit E, et al. Bilastine vs. hydroxyzine: occupation of brain histamine H1-receptors evaluated by positron emission tomography in healthy volunteers. Br J Clin Pharm. 2014;78(5):970–980. doi: 10.1111/bcp.12421Farre M., Perez-Manna C., Papaseit E., et al. Bilastine vs. hydroxyzine: occupation of brain histamine H1-receptors evaluated by positron emission tomography in healthy volunteers // Br J Clin Pharm. 2014. Vol. 78, N 5. Р. 970–980. doi: 10.1111/bcp.12421Church MK, Maurer M, Simons FE, et al. Risk of first generation H1-antihistamines: a GA(2)LEN position paper. Allergy. 2010;65(4):459–466. doi: 10.1111/j.1398-9995.2009.02325.xChurch M.K., Maurer M., Simons F.E., et al. Risk of first generation H1-antihistamines: a GA(2)LEN position paper // Allergy. 2010. Vol. 65, N 4. Р. 459-466. doi: 10.1111/j.1398-9995.2009.02325.xSimons FE, Simons KJ. Histamine and H1-antihistamines: Celebrating a century of progress. J Allergy Clin Immunol. 2011;128(6):1139–1150. doi: 10.1016/j.jaci.2011.09.005Simons F.E., Simons K.J. Histamine and H1-antihistamines: Celebrating a century of progress // J Allergy Clin Immunol. 2011. Vol. 128, N 6. Р. 1139–1150. doi: 10.1016/j.jaci.2011.09.005Mizuguchi H, Wakugawa T, Sadakata H, et al. Elucidation of inverse agonist activity of bilastine. Pharmaceutics. 2020;12(6):525. doi: 10.3390/pharmaceutics12060525Mizuguchi H., Wakugawa T., Sadakata H., et al. Elucidation of inverse agonist activity of bilastine // Pharmaceutics. 2020. Vol. 12, N 6. Р. 525. doi: 10.3390/pharmaceutics12060525Church MK, Tiongco-Recto M, Ridolo E, Novák Z. Bilastine: a lifetime companion for the treatment of allergies. Current Medical Research and Opinion. 2020;36(3):445–454. doi: 10.1080/03007995.2019.1681134Church M.K., Tiongco-Recto M., Ridolo E., Novák Z. Bilastine: a lifetime companion for the treatment of allergies // Current Medical Research and Opinion. 2020. N 36. Р. 445–454. doi: 10.1080/03007995.2019.1681134Corcóstegui R, Labeaga L, Innerárity A, et al. Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs R D. 2005;6(6):371–384. doi: 10.2165/00126839-200506060-00005Corcóstegui R., Labeaga L., Innerárity A., et al. Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity // Drugs R D. 2005. Vol. 6, N 6. Р. 371–384. doi: 10.2165/00126839-200506060-00005Horak F, Zieglmayer P, Zieglmayer R, Lemell P. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm Res. 2010;59(5):391–398. doi: 10.1007/s00011-009-0117-4Horak F., Zieglmayer P., Zieglmayer R., Lemell P. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber // Inflamm Res. 2010. Vol. 59, N 5. Р. 391–398. doi: 10.1007/s00011-009-0117-4Garcıa-Gea C, Martınez J, Ballester MR, et al. Psychomotor and subjective effects of bilastine, hydroxyzine, and cetirizine, in combination with alcohol: a randomized, double-blind, crossover, and positive-controlled and placebo-controlled Phase I clinical trials. Hum Psychopharmacol. 2014;29(2):120–132. doi: 10.1002/hup.2378Garcıa-Gea C., Martınez J., Ballester M.R., et al. Psychomotor and subjective effects of bilastine, hydroxyzine, and cetirizine, in combination with alcohol: a randomized, double-blind, crossover, and positive-controlled and placebo-controlled Phase I clinical trials // Hum Psychopharmacol. 2014. Vol. 29, N 2. Р. 120–132. doi: 10.1002/hup.2378García-Gea С, Martínez-Colomer J, Antonijoan R, et al. Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1-antihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments. J Clin Psychopharmacol. 2008;28(6):675–685. doi: 10.1097/JCP.0b013e31818b2091García-Gea С., Martínez-Colomer J., Antonijoan R., et al. Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1- antihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments // J Clin Psychopharmacol. 2008. Vol. 28, N 6. Р. 675–685. doi: 10.1097/JCP.0b013e31818b2091Valk PJ, Simons R, Jetten AM, et al. Cognitive performance effects of bilastine 20 mg during 6 hours at 8000 ft cabin altitude. Aerosp Med Hum Perform. 2016;87(7):622–627. doi: 10.3357/AMHP.4522.2016Valk P.J., Simons R., Jetten A.M., et al. Cognitive performance effects of bilastine 20 mg during 6 hours at 8000 ft cabin altitude // Aerosp Med Hum Perform. 2016. Vol. 87, N 7. Р. 622–627. doi: 10.3357/AMHP.4522.2016Reményi A, Grósz A, Szabó SA, et al. Comparative study of the effect of bilastine and cetirizine on cognitive functions at ground level and at an altitude of 4,000 m simulated in hypobaric chamber: a randomized, double-blind, placebo-controlled, cross-over study. Expert Opinion Drug Saf. 2018;17(9):859–868. doi: 10.1080/14740338.2018.1502268Reményi A., Grósz A., Szabó S.A., et al. Comparative study of the effect of bilastine and cetirizine on cognitive functions at ground level and at an altitude of 4,000 m simulated in hypobaric chamber: a randomized, double-blind, placebo-controlled, cross-over study // Expert Opinion Drug Saf. 2018. Vol. 17, N 9. Р. 859–868 doi: 10.1080/14740338.2018.1502268Tyl B, Kabbaj M, Azzam S, et al. Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QTConcentration analysis. J Clin Pharm. 2013;52(6):893–903. doi: 10.1177/0091270011407191Tyl B., Kabbaj M., Azzam S., et al. Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough qt study (TQTS) with QTConcentration analysis // J Clin Pharm. 2013. Vol. 52, N 6. Р. 893–903. doi: 10.1177/0091270011407191Graff C, Struijk J, Kanters JK, et al. Effects of bilastine on T-wave morphology and the QTc interval: a randomized, double-blind, placebo-controlled, thorough QTc study. Clin Drug Investig. 2012;32(5):339–351. doi: 10.2165/11599270-000000000-00000Graff C., Struijk J., Kanters J.K., et al. Effects of bilastine on T-wave morphology and the QTc interval: a randomized, double-blind, placebo-controlled, thorough QTc study // Clin Drug Investig. 2012. Vol. 32, N 5. Р. 339–351. doi: 10.2165/11599270-000000000-00000Kuna P, Bachert C, Nowacki Z, et al.; Bilastine International Working Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy. 2009;39(9):1338–1347. doi: 10.1111/j.1365-2222.2009.03257.xKuna P., Bachert C., Nowacki Z., et al.; Bilastine International Working Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study // Clin Exp Allergy. 2009. Vol. 39, N 9. Р. 1338–1347. doi: 10.1111/j.1365-2222.2009.03257.xBachert C, Kuna P, Sanquer F, et al.; Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy. 2009;64(1):158–165. doi: 10.1111/j.1398-9995.2008.01813.xBachert C., Kuna P., Sanquer F., et al.; Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients // Allergy. 2009. Vol. 64, N 1. Р. 158–165. doi: 10.1111/j.1398-9995.2008.01813.xSastre J, Mullol J, Valero A, et al.; Bilastine Study Group Collaborators. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis. Curr Med Res Opin. 2012;28(1):121–130. doi: 10.1185/03007995.2011.640667Sastre J., Mullol J., Valero A., et al.; Bilastine Study Group Collaborators. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis // Curr Med Res Opin. 2012. Vol. 28, N 1. Р. 121–130. doi: 10.1185/03007995.2011.640667Okubo K, Gotoh M, Asako M, et al. Efficacy and safety of bilastine in Japanese patients with perennial allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III study. Allergol Int. 2017;66(1):97–105. doi: 10.1016/j.alit.2016.05.014Okubo K., Gotoh M., Asako M., et al. Efficacy and safety of bilastine in Japanese patients with perennial allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III study // Allergol Int. 2017. Vol. 66, N 1. Р. 97–105. doi: 10.1016/j.alit.2016.05.014Okubo K, Gotoh M, Togawa M, et al. Long-term safety and efficacy of bilastine following up to 12 weeks or 52 weeks of treatment in Japanese patients with allergic rhinitis: Results of an open-label trial. Auris Nasus Larynx. 2017;44(3):294–301. doi: 10.1016/j.anl.2016.07.021Okubo K., Gotoh M., Togawa M., et al. Long-term safety and efficacy of bilastine following up to 12 weeks or 52 weeks of treatment in Japanese patients with allergic rhinitis: Results of an open-label trial // Auris Nasus Larynx. 2017. Vol. 44, N 3. Р. 294–301. doi: 10.1016/j.anl.2016.07.021Novák Z, Yáñez A, Kiss I, et al.; Bilastine Paediatric Safety Study Group. Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases. Pediatr Allergy Immunol. 2016;27(5):493–498. doi: 10.1111/pai.12555Novák Z., Yáñez A., Kiss I., et al.; Bilastine Paediatric Safety Study Group. Safety Kuna and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases // Pediatr Allergy Immunol. 2016. Vol. 27, N 5. Р. 493–498. doi: 10.1111/pai.12555Camelo-Nunes IC, Sole D. Allergic rhinitis: indicators of quality of life. J Bras Pneumol. 2010;36(1):124–133. doi: 10.1590/s1806-37132010000100017Camelo-Nunes I.C., Sole D. Allergic rhinitis: indicators of quality of life // J Bras Pneumol. 2010. Vol. 36, N 1. Р. 124–133. doi: 10.1590/s1806-37132010000100017Kirmaz C, Aydemir O, Bayrak P, et al. Sexual dysfunction in patients with allergic rhinoconjunctivitis. Ann Allergy Asthma Immunol. 2005;95(6):525–529. doi: 10.1016/S1081-1206(10)61013-7Kirmaz C., Aydemir O., Bayrak P., et al. Sexual dysfunction in patients with allergic rhinoconjunctivitis // Ann Allergy Asthma Immunol. 2005. Vol. 95, N 6. Р. 525–529. doi: 10.1016/S1081-1206(10)61013-7Locks RB, Dos Santos K, da Silva J. Quality of life in patients with allergic rhinitis: a clinical trial comparing the use of bilastine versus loratadine. Clin Otolaryngol. 2017;42(2):218–224. doi: 10.1111/coa.12695Locks R.B., Dos Santos K., da Silva J. Quality of life in patients with allergic rhinitis: a clinical trial comparing the use of bilastine versus loratadine // Clin Otolaryngol. 2017. Vol. 42, N 2. Р. 218–224. doi: 10.1111/coa.12695Jauregui I, Bartra J, del Cuvillo A, et al. Bilastine and quality of life. J Investig Allergol Clin Immunol. 2011;21(Suppl 3):16–23.Jauregui I., Bartra J., del Cuvillo A., et al. Bilastine and quality of life // J Investig Allergol Clin Immunol. 2011. Vol. 21, Suppl 3. Р. 16–23.Montoro J, Mullol J, Davila I, et al. Bilastine and the central nervous system. J Investig Allergol Clin Immunol. 2011;21(3):9–15.Montoro J., Mullol J., Davila I., et al. Bilastine and the central nervous system // J Investig Allergol Clin Immunol. 2011. Vol. 21, N 3. Р. 9–15.Vozmediano V, Sologuren A, Lukas JC, et al. Model informed pediatric development applied to bilastine: ontogenic pk model development, dose selection for first time in children and PK study design. Pharm Res. 2017;34(12):2720–2734. doi: 10.1007/s11095-017-2248-6Vozmediano V., Sologuren A., Lukas J.C., et al. Model informed pediatric development applied to bilastine: ontogenic pk model development, dose selection for first time in children and PK study design // Pharm Res. 2017. Vol. 34, N 12. Р. 2720–2734. doi: 10.1007/s11095-017-2248-6Vozmediano V, Lukas JC, Encinas E, et al. Model-informed pediatric development applied to bilastine: analysis of the clinical PK data and confirmation of the dose selected for the target population. Eur J Pharm Sci. 2019;128:180–192. doi: 10.1016/j.ejps.2018.11.016Vozmediano V., Lukas J.C., Encinas E., et al. Model-informed pediatric development applied to bilastine: analysis of the clinical PK data and confirmation of the dose selected for the target population // Eur J Pharm Sci. 2019. Vol. 128. Р. 180–192. doi: 10.1016/j.ejps.2018.11.016Bilastine 10 mg orodispersible tablets: summary of product characteristics; 2018 [cited 2021 May 24]. Available from: http://www.gov.uk/pil-spcBilastine 2.5 mg/ml oral solution: summary of product characteristics; 2018 [cited 2021 May 24]. Available from: http:// www.gov.uk/pil-spcDemoly P, Chiriac AM, Berge B, Rostin M. Reasons for prescribing second generation antihistamines to treat allergic rhinitis in real-life conditions and patient response. Allergy Asthma Clin Immun. 2014;10(1):29. doi: 10.1186/1710-1492-10-29Demoly P., Chiriac A.M., Berge B., Rostin M. Reasons for prescribing second generation antihistamines to treat allergic rhinitis in real-life conditions and patient response // Allergy Asthma Clin Immun. 2014. Vol. 10, N 1. Р. 29. doi: 10.1186/1710-1492-10-29Demoly P, Aubier M, de Blay F, et al. Evaluation of patients’ expectations and benefits in the treatment of allergic rhinitis with a new tool: the patient benefit index – the benefica study. Allergy Asthma Clin Immunol. 2015;11(1):8. doi: 10.1186/s13223-015-0073-1Demoly P., Aubier M., de Blay F., et al. Evaluation of patients’ expectations and benefits in the treatment of allergic rhinitis with a new tool: the patient benefit index – the benefica study // Allergy Asthma Clin Immunol. 2015. Vol. 11, N 1. Р. 8. doi: 10.1186/s13223-015-0073-1Lynde CW, Sussman GB, Dion PL, et al. Multidisciplinary real-world experience with bilastine, a second generation antihistamine. J Drugs Dermatol. 2020;19(2):145–154. doi: 10.36849/JDD.2020.4835.Lynde C.W., Sussman G.B., Dion P.L., et al. Multidisciplinary real-world experience with bilastine, a second generation antihistamine // J Drugs Dermatol. 2020. Vol. 19, N 2. Р. 145–154. doi: 10.36849/JDD.2020.4835.